2025年甲状腺癌年度进展报告

doi:null

您当前的位置：

首页 >

文章列表页 >

2025年甲状腺癌年度进展报告

更新时间：2026-02-11

- 2025年甲状腺癌年度进展报告
- China Oncology (2026)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC：
- Received：11 February 2026，
- 稿件说明：
移动端阅览
2025年甲状腺癌年度进展报告[J/OL]. China Oncology, 2026.
DOI：

2025年甲状腺癌年度进展报告[J/OL]. China Oncology, 2026. DOI：

摘要

近年来，随着分子生物学、影像学及循证医学证据的不断积累，甲状腺癌的诊疗模式正经历系统性重塑。分化型甲状腺癌（differentiated thyroid carcinoma，DTC）整体预后良好，但在不同风险人群中呈现出显著的生物学与临床异质性；与此同时，低分化甲状腺癌（poorly differentiated thyroid carcinoma，PDTC）和未分化甲状腺癌（anaplastic thyroid carcinoma，ATC）仍以高度侵袭性、进展迅速和治疗选择有限为特征，构成甲状腺癌相关死亡的主要来源。如何基于肿瘤生物学特征与疾病演进阶段，实现精准分层管理与治疗策略优化，已成为当前领域关注的核心问题。

进入

2025 年，循证医学证据的积累与技术革新共同推动了这一领域的系统性重塑。一方面，临床诊疗指南持续更新，以风险分层和动态评估为核心，推动早期 DTC 向个体化和长期生存质量导向的管理模式转型；另一方面，人工智能（artificial intelligence

AI）辅助诊断、新型分子显像技术及多组学分析的快速发展，正在重塑甲状腺癌的诊断路径与风险评估体系。对于晚期及放射性碘难治性（radioiodine-refractory

RAIR）患者，分子靶向治疗、免疫治疗及再分化策略不断拓展治疗边界，而以嵌合抗原受体T(chimeric antigen receptor T

CAR-T)等细胞治疗为代表的创新疗法也开始进入临床探索阶段。与此同时，基础研究的研究范式正在发生转变：研究焦点从单一驱动突变逐步拓展至肿瘤代谢重塑、表观遗传调控及肿瘤微环境（tumor microenvironment

TME）的系统互作。多组学整合与空间转录组技术揭示，ATC的高度侵袭性并非仅由肿瘤细胞内在异常决定，而是依赖于免疫抑制性微环境、代谢重编程及细胞间信号网络的协同塑造，为联合治疗和微环境靶向干预提供了新的理论基础。基于上述背景，本文将系统梳理 2025 年甲状腺癌领域在临床诊疗指南更新、诊断技术革新、系统治疗策略演进及基础研究机制突破等方面的关键进展，旨在为临床实践与未来研究方向提供综合性的参考框架。

Abstract

In recent years

the continuous accumulation of evidence from molecular biology

medical imaging

and evidence-based medicine has driven a systematic reshaping of diagnostic and therapeutic paradigms for thyroid cancer. Differentiated thyroid carcinoma (DTC) is generally associated with a favorable prognosis; however

marked biological and clinical heterogeneity exists across different risk populations. In contrast

poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC) remain characterized by high aggressiveness

rapid progression

and limited therapeutic options

accounting for the majority of thyroid cancer–related mortality. How to achieve precise risk stratification and optimize therapeutic strategies based on tumor biology and disease stage has therefore emerged as a central challenge in the field.

Entering 2025

the integration of expanding evidence-based data and technological innovation has further accelerated this paradigm shift. On the one hand

continuous updates to clinical practice guidelines—centered on risk stratification and dynamic assessment—have promoted a transition in early-stage DTC management toward individualized care and long-term quality-of-life–oriented strategies. On the other hand

advances in artificial intelligence (AI)–assisted diagnostics

novel molecular imaging techniques

and multi-omics analyses are redefining diagnostic pathways and risk assessment frameworks for thyroid cancer. For patients with advanced disease and radioiodine-refractory (RAIR) thyroid cancer

the therapeutic landscape continues to expand with the development of molecular targeted therapies

immunotherapy

and redifferentiation strategies. In parallel

innovative approaches such as cell-based therapies

exemplified by chimeric antigen receptor T (CAR-T) cell therapy

have begun to enter early-phase clinical exploration.

Meanwhile

fundamental research paradigms are undergoing a notable shift. Research focus is moving beyond single driver mutations toward a systems-level understanding encompassing tumor metabolic reprogramming

epigenetic regulation

and complex interactions within the tumor microenvironment (TME). Integrative multi-omics and spatial transcriptomic analyses have revealed that the extreme aggressiveness of ATC is not solely determined by tumor cell–intrinsic abnormalities

but rather arises from the coordinated influence of immunosuppressive microenvironments

metabolic remodeling

and intercellular signaling networks. These insights provide a theoretical foundation for combination therapies and microenvironment-targeted interventions.

Against this background

this review systematically summarizes the key advances in thyroid cancer research in 2025

including updates to clinical practice guidelines

innovations in diagnostic technologies

evolution of systemic treatment strategies

and breakthroughs in mechanistic studies

with the aim of providing a comprehensive reference framework for clinical practice and future research directions.

关键词

Keywords

references

RINGEL M D , SOSA J A , BALOCH Z , et al . 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer [J ] . Thyroid : official journal of the American Thyroid Association , 2025 , 35 ( 8 ): 841 - 985 .

CHOU R , DANA T , HAYMART M , et al . Active Surveillance Versus Thyroid Surgery for Differentiated Thyroid Cancer: A Systematic Review [J ] . Thyroid : official journal of the American Thyroid Association , 2022 , 32 ( 4 ): 351 - 67 .

ITO Y , URUNO T , NAKANO K , et al . An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid [J ] . Thyroid : official journal of the American Thyroid Association , 2003 , 13 ( 4 ): 381 - 7 .

DUNN L A , SHERMAN E J , BAXI S S , et al . Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers [J ] . The Journal of Clinical Endocrinology and Metabolism , 2019 , 104 ( 5 ): 1417 - 28 .

HO A L , GREWAL R K , LEBOEUF R , et al . Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer [J ] . N Engl J Med , 2013 , 368 ( 7 ): 623 - 32 .

WELLS S A , ASA S L , DRALLE H , et al . Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma [J ] . Thyroid : official journal of the American Thyroid Association , 2015 , 25 ( 6 ): 567 - 610 .

ITO Y , ONODA N , OKAMOTO T . The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons: Core questions and recommendations for treatments of thyroid cancer [J ] . Endocr J , 2020 , 67 ( 7 ): 669 - 717 .

SHI X , SHEN C , LIU C , et al . Hemithyroidectomy Versus Total Thyroidectomy for Sporadic Medullary Thyroid Cancer: A Chinese Nationwide Large-Scale Cohort Study [J ] . J Natl Compr Canc Netw , 2025 , 23 ( 3 ): 105 - 12 .

SHEN C , DU Y , XIANG S , et al . Revised Perspective on the AJCC Staging System for Medullary Thyroid Cancer: A Study of Two Nationwide Cohorts [J ] . J Natl Compr Canc Netw , 2025 , 23 ( 4 ).

XU B , FUCHS T L , AHMADI S , et al . International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma [J ] . J Clin Oncol , 2021 , 40 ( 1 ).

PRETE A , TORREGROSSA L , GAMBALE C , et al . The Usefulness of the International Grading System in the Management of Sporadic Medullary Thyroid Carcinoma [J ] . Thyroid : official journal of the American Thyroid Association , 2025 , 35 ( 4 ): 387 - 96 .

SHEN P , YANG Z , SUN J , et al . Explainable multimodal deep learning for predicting thyroid cancer lateral lymph node metastasis using ultrasound imaging [J ] . Nature communications , 2025 , 16 ( 1 ): 7052 .

LOU Y , SU Y , LU H , et al . Cytological Classification Diagnosis for Thyroid Nodules via Multimodal Model Deep Learning [J ] . Adv Sci (Weinh) , 2025 , 12 ( 48 ): e11369 .

KONG Z , LI Z , CUI X-Y , et al . CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma [J ] . Cancer Discovery , 2025 , 15 ( 2 ): 316 - 28 .

NING K , CHEN Q , GUO Y , et al . Efficacy and safety of immunotherapy in anaplastic thyroid carcinoma: a systematic review and meta-analysis [J ] . Int J Surg , 2025 , 112 ( 1 ): 1708 - 21 .

ZHANG Y , DU X , CAI S , et al . Developing a thyroid cancer differentiation state classification system using deep residual networks and metabolic signature profiling [J ] . NPJ Digit Med , 2025 , 8 ( 1 ): 572 .

PAN Z , TAN Z , XU N , et al . Integrative proteogenomic characterization reveals therapeutic targets in poorly differentiated and anaplastic thyroid cancers [J ] . Nature communications , 2025 , 16 ( 1 ): 3601 .

HOU X , DONG Q , HAO J , et al . NSUN2-mediated m5C modification drives alternative splicing reprogramming and promotes multidrug resistance in anaplastic thyroid cancer through the NSUN2/SRSF6/UAP1 signaling axis [J ] . Theranostics , 2025 , 15 ( 7 ): 2757 - 77 .

DAI B , LI J , XU L , et al . YTHDF2-mediated stabilization of SREBF1 promotes lipid metabolic reprogramming and ferroptosis-associated radioresistance in anaplastic thyroid carcinoma [J ] . Cancer Lett , 2025 , 639 : 218232 .

TIAN X , PENG K , ZHAO T , et al . ZEB1 and ALKBH5 coregulate CRABP2 and FABP5 and jointly determine the sensitivity of anaplastic thyroid cancers to gemcitabine and retinoic acid [J ] . NPJ Precis Oncol , 2025 , 9 ( 1 ): 334 .

ZHANG Y , SU W , JI X , et al . PCSK9 promotes progression of anaplastic thyroid cancer through E-cadherin endocytosis [J ] . Cell Death Dis , 2025 , 16 ( 1 ): 362 .

ZHANG S , HAN B , JIANG B , et al . USP14 and UCHL5 synergistically deubiquitinate PKCα and translocate NF-κB to promote the progression of anaplastic thyroid cancer [J ] . Cell Death Dis , 2025 , 16 ( 1 ): 617 .

MA B , SANG Y , DU X , et al . Targeting CDK2 Confers Vulnerability to Lenvatinib Via Driving Senescence in Anaplastic Thyroid Cancer [J ] . Adv Sci (Weinh) , 2024 , 12 ( 7 ): e2413514 .

TIEDJE V , GREENBERG J , QIN T , et al . Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers [J ] . The Journal of Clinical Investigation , 2025 , 135 ( 20 ).

NING K , ZOU B , YU Y , et al . Spatial Transcriptomics Reveals Transcriptomic and Immune Microenvironment Reprogramming during Thyroid Carcinoma Dedifferentiation [J ] . Adv Sci (Weinh) , 2025 , 12 ( 44 ): e06925 .

PAN Z , CHEN J , XU T , et al . VSIG4+ tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1 [J ] . J Exp Clin Cancer Res , 2025 , 44 ( 1 ): 45 .

LIU Q , WANG Y , SONG M , et al . CCL20/CXCL5 Drives Crosstalk Between Anaplastic Thyroid Cancer Stem Cells and Tumor-Associated Macrophages to Promote Tumor Progression [J ] . Adv Sci (Weinh) , 2025 , 12 ( 17 ): e2405399 .

LIAO T , ZENG Y , XU W , et al . A spatially resolved transcriptome landscape during thyroid cancer progression [J ] . Cell Reports Medicine , 2025 , 6 ( 4 ): 102043 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: advances in surgical treatment of differentiated thyroid cancer

Mechanisms of PTEN-regulated PDK1 in modulating malignant phenotypes of clear cell renal cell carcinoma

Survival and cause-of-death analysis of 55 thousand thyroid cancer cases in China from a large single institution hospital-based cancer registry database

Current status and prospect of diagnosis and treatment of bone metastasis of thyroid cancer

Research progress in epidemiology and risk factors of thyroid cancer

Related Author

Jugao FANG

Qian SHI

Shuangshuang DUAN

Abudusaimaiti GULINAIZAIER

Lijun ZHANG

Miao SUN

Huibin LIU

Qinghai JI

Related Institution

Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University

Clinical Trial Institution, Xinjiang Medical University Affiliated Cancer Hospital, Urumqi 830000, XinJiang Uygur Autonomous Region

College of Pharmacy, Xinjiang Medical University, Urumqi 830000, XinJiang Uygur Autonomous Region

Shanghai Engineering Research Center of Artificial Intelligence Technology for Tumor Diseases

School of Public Health, Fudan University

AI问答

⁰